AI assistant
LISATA THERAPEUTICS, INC. — Director's Dealing 2016
Jan 27, 2016
34931_dirs_2016-01-27_1b8a9510-c012-4b78-8c9b-69426ffb50ca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2016-01-25
Reporting Person: Preti Robert A (Director, See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-01-25 | Common Stock | A | 76000 | — | Acquired | 270989 | Direct |
| 2016-01-25 | Common Stock | F | 7534 | $0.63 | Disposed | 263455 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-01-25 | Options to Purchase Common Stock | $0.63 | A | 125000 | Acquired | 2026-01-25 | Common Stock (125000) | Direct |
Footnotes
F1: Represents 76,000 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. 25% of the shares of restricted stock vest immediately on the grant date and the remaining 75% of the shares of restricted stock will vest quarterly over the following 12 quarters.
F2: Includes 57,000 shares of unvested restricted stock.
F3: 25% of the shares underlying the Options vest immediately on the grant date and the remaining 75% of the shares underlying the Options will vest quarterly over the following 12 quarters.